References

Liang Y, Meng Z, Ding XL, Jiang M Effects of proton pump inhibitors on inflammatory bowel disease: An updated review. World J Gastroenterol. 2024; 30:(21)2751-2762 https://doi.org/10.3748/wjg.v30.i21.2751

Masarwa R, Reynier P, Lefebvre C, Platt RW, Delaney JAC, Filion KB Prescribing trends of proton pump inhibitors and histamine blockers among children in the United Kingdom (1998-2019): A population-based assessment. Pharmacoepidemiol Drug Saf. 2024; 33:(2) https://doi.org/10.1002/pds.5752

NHS Business Services Authority. Prescription Cost Analysis England 2022/23. 2023. https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/pca/pca_summary_narrative_2022_23_v001.html (accessed 19 December 2024)

Page MJ, McKenzie JE, Bossuyt PM The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372 https://doi.org/10.1136/bmj.n71

Rossi A, Perrella L, Scotti S, Olmastroni E, Galimberti F, Ardoino I, Orlando V, Menditto E, Franchi C, Casula M Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review. J Clin Med. 2024; 13:(20) https://doi.org/10.3390/jcm13206283

Prescribing proton pump inhibitors

02 January 2025
Volume 7 · Issue 1

Abstract

Deborah Robertson provides an overview of recently published articles that may be of interest to non-medical prescribers. Should you wish to look at any of the papers in more detail, a full reference is provided

Last month, the research round-up provided you with an overview looking at prescribing and management of the menopause. This month, we will review three articles on the prescribing of proton pump inhibitors (PPIs) across a range of areas. The first is a study examining prescribing trends in children in the UK. The second article is a systematic review of approaches to deprescribing of PPIs in clinical practice. Finally, in our third article we look at a review of the effects of PPIs on inflammatory bowel disease.

This article, published in the journal Pharmacoepidemiology and Drug Safety, sought to describe the prescribing trends of PPIs and H2 receptor antagonists (H2RAs) among children with gastroesophageal reflux in the UK between 1998 and 2019.

This study was conducted using a population-based retrospective methodology approach and included data over the time period of 1998–2019 collected from the Clinical Practice Research Datalink (CPRD) Aurum, a database comprising clinical data from over 19 million patients enrolled with around 70 general practices in the UK.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month